Senior Clinician, Genitourinary Malignancies Branch, NCI
Review begins: January 8, 2024
The Center for Cancer Research (CCR), a division of the National Cancer Institute (NCI), National Institutes of Health (NIH), announces a call for applications for a Senior Clinician focused on prostate cancer in the Genitourinary Malignancies Branch (GMB). The GMB has established a robust, internationally recognized prostate research program.
The GMB has strong collaborations with prostate cancer investigators in the Urologic Oncology Branch, Radiation Oncology Branch, and other basic and translational scientists throughout the CCR. Current research within the branch focuses on the management of biochemical recurrence after local therapy for prostate cancer, the use of imaging to determine optimal timing and type of therapy for metastatic prostate cancer, and the use of focal radiation combined with immunocytokines. Clinical trials include interventions such as immunotherapy, radiopharmaceuticals, anti-androgens, and novel targeted therapies. The GMB seeks to broaden the focus of its prostate research program in the neoadjuvant and advanced prostate disease, including early disease interception in patients with high genetic risk, cancer genomics, and investigation of precision therapies (PARP inhibitors, antibody drug conjugates, etc.) in the advanced disease setting. This is an opportunity to leverage the unique strengths of the intramural setting for in-depth study of pharmacodynamic endpoints in the tumor (using tissue from neoadjuvant studies) that can be used to understand the biological impacts and guide rational clinical trial designs in the metastatic setting. The GMB is seeking a skilled physician-scientist to lead this clinical area.
The CCR is an intramural research component of the NCI located in Bethesda, Maryland. CCR’s enabling infrastructure facilitates clinical studies at the NIH Clinical Center, the nation's largest hospital devoted entirely to clinical research; it provides extensive opportunities for collaboration and allows scientists and clinicians to undertake high-impact laboratory- and clinic-based investigations. Our research teams conduct over 300 clinical research trials with >50 new trials, enrolling >1,300 new patients, opening annually. Clinical investigators are supported by a wide array of supportive clinical resources, including data management, research nursing, patient care coordination, education, protocol development support, patient referral and outreach, and technology transfer collaborations with industry. The CCR is fully committed to and is taking actionable steps to create a fully equitable work environment, build a diverse cancer research workforce, expand health disparities research, and improve patient representation in clinical trials. Our scientists enjoy complete intellectual freedom and are expected to creatively and innovatively explore the most important questions in the field of cancer research and treatment. We support projects over a long-time horizon allowing our investigators to pursue some of the most difficult, high-risk problems in the field. For an overview of CCR, please visit http://ccr.cancer.gov.
Eligibility: Applicants must hold an M.D., D.O., or equivalent degree, be board-certified or board-eligible in medical oncology, and have significant experience and skill in developing and executing early-phase clinical trials on human subjects using a variety of cutting-edge approaches to improve prostate cancer treatment, such as PARP inhibition, immune checkpoint therapy and genomic characterization of cancer and treatment response. Candidates may be U.S. citizens, permanent residents, or possess (or be eligible for) an appropriate work visa and must have successfully completed subspecialty training at a U.S. accredited institution.
Salary and Benefits: Salary is commensurate with education and experience. A full federal benefits package is available, including retirement, health insurance, life insurance, annual and sick leave, and the Thrift Savings Plan (401K equivalent).
How to Apply: Interested applicants should submit:
- A letter of interest in the position, including a career synopsis addressing your qualifications for the position and experience in patient care, research, supervision, and mentoring.
- A current curriculum vitae and complete bibliography.
- A diversity statement describing your track record of and commitment to promoting diversity, equity, and inclusion in biomedical research and/or medicine, including, but not limited to, the understanding of and impacting issues of equity, inclusion, and diversity, successful recruitment and/or mentorship of individuals from historically underrepresented groups, demonstrated sustained efforts to promote diversity, equity and inclusion, and plans for addressing diversity and inclusion in the future. (500-word limit).
Applications must be submitted to: https://service.cancer.gov/ccr-careers. Initial review of applications will begin on or about January 8, 2024, but applications will be accepted until the position is filled. Applications will be treated as confidential. For more information, contact Patrick Miller, Faculty Recruitment Coordinator, at email@example.com.
Selection for this position will be based solely on merit, with no discrimination for non-merit reasons such as race, color, religion, gender, sexual orientation, national origin, political affiliation, marital status, disability, age, or membership or non-membership in an employee organization. NIH provides reasonable accommodations to applicants with disabilities. If you require reasonable accommodation during any part of the application and hiring process, please notify us. The decision on granting reasonable accommodation will be made on a case-by-case basis. This position is subject to a background investigation.
The NCI and the CCR are deeply committed to diversity of thought, equity and inclusion and encourages applications from qualified women, under-represented groups, and individuals with disabilities. HHS, NIH, and NCI are Equal Opportunity Employers
This page was last updated on Tuesday, November 7, 2023